Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-07-22

Clinical Trial Update: INSULIN THERAPY DE-INTENSIFICATION WITH iGlarLixi [Phase 4]

View source ↗

Summary

Phase 4 trial update on de-intensifying insulin therapy using iGlarLixi in patients with Type 2 diabetes treated with insulin.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • iGlarLixi (insulin glargine + lixisenatide)

Snippet

Sponsor: Institute for Clinical and Experimental Medicine | Conditions: Type 2 Diabetes Treated With Insulin | Phase 4 | Status: UNKNOWN